MAPK10 and CDKN2C

Number of citations of the paper that reports this interaction (PubMedID 16007099)
30

Data Source:
BioGRID (pull down)

		MAPK10	CDKN2C
Description		mitogen-activated protein kinase 10	cyclin dependent kinase inhibitor 2C
Image
GO Annotations	Cellular Component	Nucleus Nucleoplasm Cytoplasm Mitochondrion Cytosol Plasma Membrane Neuron Projection Perikaryon Glutamatergic Synapse	Nucleus Cytoplasm Cytosol
	Molecular Function	Protein Serine/threonine Kinase Activity JUN Kinase Activity MAP Kinase Activity MAP Kinase Kinase Activity Protein Binding ATP Binding Protein Serine Kinase Activity	Cyclin-dependent Protein Serine/threonine Kinase Inhibitor Activity Protein Binding Protein Kinase Binding
	Biological Process	Negative Regulation Of Transcription By RNA Polymerase II Protein Phosphorylation Signal Transduction JNK Cascade JUN Phosphorylation Response To Water Deprivation Response To Light Stimulus Intracellular Signal Transduction Fc-epsilon Receptor Signaling Pathway Regulation Of Circadian Rhythm Rhythmic Process Regulation Of DNA-binding Transcription Factor Activity Cellular Hyperosmotic Response Cellular Senescence Neurotransmitter Receptor Transport To Postsynaptic Membrane Vesicle-mediated Transport In Synapse	Regulation Of Cyclin-dependent Protein Serine/threonine Kinase Activity G1/S Transition Of Mitotic Cell Cycle Negative Regulation Of Cell Population Proliferation Negative Regulation Of Cell Growth Negative Regulation Of Phosphorylation Negative Regulation Of Cyclin-dependent Protein Serine/threonine Kinase Activity Oligodendrocyte Differentiation Regulation Of Cell Cycle
Pathways		Oxidative Stress Induced Senescence FCERI mediated MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 Activation of the AP-1 family of transcription factors	Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1
Drugs		Minocycline Pyrazolanthrone Cyclohexyl-{4-[5-(3,4-Dichlorophenyl)-2-Piperidin-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine Cyclopropyl-{4-[5-(3,4-Dichlorophenyl)-2-[(1-Methyl)-Piperidin]-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine 9-(4-Hydroxyphenyl)-2,7-Phenanthroline Phosphoaminophosphonic Acid-Adenylate Ester N-(tert-butyl)-4-[5-(pyridin-2-ylamino)quinolin-3-yl]benzenesulfonamide N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide 4-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-N-ethylpiperidine-1-carboxamide (3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime (3E)-5-fluoro-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-1H-indole-2,3-dione 3-oxime (3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-phenyl-1H-indole-2,3-dione 3-oxime 5-bromo-N-(3-chloro-2-(4-(prop-2-ynyl)piperazin-1-yl)phenyl)furan-2-carboxamide N-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-N-methylpyrimidin-2-amine N-{2'-[(4-FLUOROPHENYL)AMINO]-4,4'-BIPYRIDIN-2-YL}-4-METHOXYCYCLOHEXANECARBOXAMIDE 2-{4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]piperidin-1-yl}-N-methylacetamide 1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline Fostamatinib Halicin
Diseases
GWAS		Cleft lip with or without cleft palate x maternal periconceptional smoking interaction (parent of origin effect) ( 31372216) Cobalt levels ( 26025379) Diisocyanate-induced asthma ( 25918132) Gait speed in old age ( 28077804) Liver enzyme levels (alanine transaminase) ( 33972514 22001757) Multiple sclerosis ( 31604244) Peripheral artery disease ( 25009551) Response to cytidine analogues (gemcitabine) ( 24483146) Triglyceride levels ( 32203549 32154731)	Atrial fibrillation ( 29290336) Brain morphology (min-P) ( 32665545) Brain morphology (MOSTest) ( 32665545) Cataracts ( 34127677) Cataracts (operation) ( 31816047) Cortical surface area (min-P) ( 32665545) Cortical surface area (MOSTest) ( 32665545) Cortical thickness (min-P) ( 32665545) Cortical thickness (MOSTest) ( 32665545) Height ( 31562340 33713608) Hip circumference adjusted for BMI ( 34021172) Hippocampal tail volume (corrected for total hippocampal volume) ( 30279459) Ischemic stroke (large artery atherosclerosis) ( 26732560) Male-pattern baldness ( 28196072) Pulse pressure ( 30578418) QRS complex (12-leadsum) ( 27659466) QRS duration ( 27577874 21076409 27659466) Subcortical volume (min-P) ( 32665545) Subcortical volume (MOSTest) ( 32665545) Thyroid stimulating hormone levels ( 32769997) Ventricular ectopy ( 29618737) Ventricular ectopy or supraventricular ectopy (pleiotropy) ( 29618737)
Interacting Genes		40 interacting genes: APP ARRB1 ARRB2 ATF2 BCL2L11 CDK5 CDKN1B CDKN2A CDKN2C CEP290 CREBBP DUSP10 DUSP16 DUSP9 ELK1 FBXO7 GTF3C1 HAX1 HDAC9 HNRNPK HRAS JUN KIF26A KIF5A LDHA MAP2K4 MAPK8IP2 MAPK8IP3 MAPKBP1 MAPT MCL1 PKMYT1 PLIN2 RELA SH3BP5 STMN2 TNIP1 TP53 UBE3A UNC119	58 interacting genes: AHCYL1 AKT1 ANGPTL4 APLP1 ARNT ATM ATR CCDC90B CCND2 CCNE1 CDK4 CDK6 CDKN2A CDKN2B COPS6 CRX CTDSP1 DRAP1 EPHA2 ERBB2 FGFR4 GDF9 GOPC GREB1 GRM1 KRT31 LATS2 LNX2 LRIF1 LY96 MAP2K3 MAP2K5 MAPK10 MAPK8 MTA3 MYC NAGK NAT2 NF2 NIF3L1 PBX4 PDGFRA PLEKHG4 POU6F2 PPP2CA RAF1 RBM48 REL SCGB2A2 SNU13 SORBS3 ST14 STK11 TCF12 TCF4 TLE1 TP53 UNC119
Entrez ID		5602	1031
HPRD ID		04207	04534
Ensembl ID		ENSG00000109339	ENSG00000123080
Uniprot IDs		A0A1P0B7D2 A0A286YEQ7 A0A286YES0 A0A286YF02 A0A286YF97 A0A286YFD7 A0A286YFN2 D6RCB1 D6RJF9 F8W9R5 I6L9F3 P53779 Q499Y8	P42773 Q6ICV4
PDB IDs		1JNK 1PMN 1PMU 1PMV 2B1P 2EXC 2O0U 2O2U 2OK1 2P33 2R9S 2WAJ 2ZDT 2ZDU 3CGF 3CGO 3DA6 3FI2 3FI3 3FV8 3G90 3G9L 3G9N 3KVX 3OXI 3OY1 3PTG 3RTP 3TTI 3TTJ 3V6R 3V6S 4H36 4H39 4H3B 4KKE 4KKG 4KKH 4U79 4W4V 4W4W 4W4X 4W4Y 4WHZ 4X21 4Y46 4Y5H 4Z9L 6EKD 6EMH 6EQ9 7KSI 7KSJ 7KSK	1BU9 1G3N 1IHB 1MX2 1MX4 1MX6
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?